A new study published in PNAS reveals that cancer patients who receive hematopoietic cell transplants from donors with lower socioeconomic status experience reduced overall survival and increased transplant-related mortality. The research highlights the profound impact of social inequality on health outcomes, particularly in cancer care.
SourceUniversity of Minnesota Medical School·JournalProceedings of the National Academy of Sciences·TypeData/statistical analysis·DateJul 17, 2024
A new study predicts patient outcomes for blood cancer treatment using personalized simulations based on genomic sequencing data. The approach successfully identifies patients with varying prognoses across multiple datasets, providing robust predictions despite mutational heterogeneity.
SourceUniversity of Sussex·JournalBlood Cancer Journal·DateJul 15, 2024
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
SourceUniversity of Plymouth·JournalEBioMedicine·TypeExperimental study·DateJul 10, 2024
A phase II clinical trial found trametinib effective in treating pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML), with seven of ten patients alive after two years. The treatment showed antitumor activity and downregulated inflammatory signaling, offering hope for JMML patients and their families.
SourceAmerican Association for Cancer Research·JournalCancer Discovery·DateJun 13, 2024
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
A large Stanford Medicine study has found that the risk of secondary blood cancers after CAR-T cell therapy is low, around 6.5% in three years. The therapy did not introduce lymphoma into patients with pre-existing cancer cells, which were already present at low levels.
SourceStanford Medicine·JournalNew England Journal of Medicine·TypeData/statistical analysis·DateJun 12, 2024
A new detailed analysis of a patient's second cancer after receiving CAR-T therapy provides valuable guidance for clinicians. The study reveals that CAR-T related second cancers can occur, often with lymphomas, and highlights the need for early detection and management.
SourceGeorgetown University Medical Center·JournalNew England Journal of Medicine·TypeCase study·DateJun 12, 2024
Researchers developed a nine-week, phone-delivered positive psychology program called PATH to improve psychological well-being in blood cancer patients. The intervention had promising effects on patient-reported outcomes, with high participation and completion rates.
SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateJun 11, 2024
Researchers at UC Davis Health discovered that mesalamine can replace good bacteria's work in fighting Candida albicans in the gut. The study found that mesalamine maintains a low oxygen environment that prevents fungal growth, reducing the risk of invasive candidiasis.
SourceUniversity of California - Davis Health·JournalCell Host & Microbe·TypeExperimental study·DateJun 4, 2024
Garmin GPSMAP 67i with inReach
Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
SourceUniversity of Pennsylvania School of Medicine·DateJun 1, 2024
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
The FDA committee voted unanimously to approve minimal residual disease (MRD) as a new clinical endpoint for evaluating proposed drugs to treat multiple myeloma. A meta-analysis led by C. Ola Landgren shows a strong correlation between MRD and clinical outcomes in newly diagnosed and relapsed patients.
SourceUniversity of Miami Miller School of Medicine·JournalBlood·DateMay 21, 2024
Scientists have discovered 17 new genes involved in clonal haematopoiesis, a process associated with ageing linked to increased risks of blood cancers. The findings highlight the clinical significance of these genes in driving mutant blood cell clones, offering new avenues for studying disease development and promoting healthier ageing.
SourceWellcome Trust Sanger Institute·JournalNature Genetics·TypeObservational study·DateMay 14, 2024
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Researchers at Goethe University Frankfurt have discovered thalidomide derivatives that target and degrade BCL-2, a protein essential for the survival of cancer cells. The derivatives bind to CRBN, reprogramming its binding surface to mark BCL-2 for degradation, ultimately leading to cell death.
SourceGoethe University Frankfurt·JournalCell Reports Physical Science·TypeExperimental study·DateMay 13, 2024
A third Covid vaccine dose has been shown to improve defensive antibody responses in some clinically extremely vulnerable patients. The trial found that 90% of patients who received a booster dose developed significant antibodies, but more than half of those with low initial responses saw no improvement.
SourceUniversity of Birmingham·JournalThe Lancet Rheumatology·TypeRandomized controlled/clinical trial·DateMay 8, 2024
A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.
SourceVirginia Tech·JournalJAMA Oncology·TypeData/statistical analysis·DateMay 2, 2024
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
A new genetic testing procedure identifies patients at high cardiovascular risk due to clonal haematopoiesis and carotid artery stenosis. This allows for early detection of increased mortality and a personalized cardiovascular risk profile, enabling therapy adaptation and prevention of atherosclerotic disease progression.
SourceMedical University of Vienna·JournalJournal of the American College of Cardiology·DateApr 30, 2024
A novel combination of two existing drugs has been discovered to eradicate AML cancer cells in lab-based tests, offering hope for patients diagnosed annually with the disease. The treatment, pairing venetoclax with a STING agonist, showed high promise in AML samples driven by a mutated p53 protein, a type of AML generally harder to treat.
SourceWalter and Eliza Hall Institute·JournalCancer Cell·TypeObservational study·DateApr 30, 2024
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
SourceCactus Communications·JournalChinese Medical Journal·TypeLiterature review·DateApr 24, 2024
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Researchers have developed a urine-based test that detects pieces of DNA fragments released by head and neck tumors, providing a non-invasive alternative to traditional blood-based biomarker tests. The test has been shown to detect cancer recurrences far earlier than would typically happen based on clinical imaging.
SourceMichigan Medicine - University of Michigan·JournalJCI Insight·TypeExperimental study·DateApr 16, 2024
Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.
SourceCactus Communications·JournalChinese Medical Journal·TypeLiterature review·DateApr 10, 2024
Researchers used single-molecule microscopy and X-ray crystallography to discover that pathogenic JAK2 mutations utilize pseudokinase domain-mediated dimerization as a mechanism for activation. The study provides new insights into the molecular basis of JAK2 activation and its role in blood cancers.
SourceTampere University·JournalScience Advances·DateApr 3, 2024
Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel antibody-drug conjugate (ADC) therapy that effectively kills T-cell cancers in mice with human T-cell tumors. The treatment targets TRBC1 protein expressed on the surface of cancer cells while preserving normal T cells.
SourceJohns Hopkins Medicine·JournalNature·DateApr 2, 2024
Researchers developed a method using lipid nanoparticles to activate T cells and deliver genetic instructions in one step, simplifying the CAR T cell manufacturing process. This new approach reduces production time from 48 hours to 24 hours and increases accessibility to patients worldwide.
SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalAdvanced Materials·TypeExperimental study·DateMar 27, 2024
GoPro HERO13 Black
GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.
Researchers at RCSI have identified a new treatment option for multiple myeloma by combining venetoclax with 5-azacytidine. This combination shows enhanced efficacy across various patient samples and has the potential to expand treatment options for those resistant to standard care.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
SourceUniversity of Zurich·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 21, 2024
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.
SourceNational University of Singapore·JournalBlood Cancer Discovery·TypeExperimental study·DateMar 19, 2024
A study published in Cell Stem Cell found that restricting iron levels in blood stem cells can reverse their decline and improve regenerative capacity. The researchers discovered that excess intracellular iron activates inflammation within HSCs, while restricted iron levels enable them to multiply and respond effectively.
SourceAlbert Einstein College of Medicine·JournalCell Stem Cell·TypeExperimental study·DateMar 8, 2024
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.
SourceGoethe University Frankfurt·JournalBlood·TypeMeta-analysis·DateMar 1, 2024
A recent study published in JAMA Network Open found that vaccinated adults with hematologic cancers were at high risk of severe COVID-19, even after receiving treatment. The study included 6,122 patients and showed no significant decline in severe cases through mid-2022.
SourceJAMA Network·JournalJAMA Network Open·DateFeb 23, 2024
A team of researchers from the University of Tokyo demonstrated that a drug, valemetostat, reduces tumor growth in blood cancer by targeting H3K27me3, a protein modification silencing tumor suppressor genes. The treatment restores expression of many tumor suppressor genes and sustains inhibiting tumor cell growth.
SourceUniversity of Tokyo·JournalNature·TypeRandomized controlled/clinical trial·DateFeb 21, 2024
A phase 2 study by Mount Sinai-led researchers demonstrates rusfertide's ability to limit excess red blood cell production in patients with polycythemia vera, a rare and chronic blood cancer. The results suggest it could replace therapeutic phlebotomy, providing improved treatment options for patients.
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateFeb 21, 2024
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
SourceUniversity of Birmingham·JournalNature Communications·TypeExperimental study·DateFeb 15, 2024
Apple iPad Pro 11-inch (M4)
Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.
A study published in Blood Advances found that combination therapies can significantly reduce blood pressure in patients taking ibrutinib. The research suggests that different drug combinations may be more effective depending on whether patients had high blood pressure before or developed it while taking the drug.
SourceAmerican Society of Hematology·JournalBlood Advances·DateFeb 5, 2024
Researchers discovered a link between single cancer cell mutations and clinical response to epigenetic therapy in myelodysplastic syndrome. Patients showing treatment benefits had decreased mutation counts in stem cells and immature granulocytes, suggesting early tumor elimination is key to therapy success.
SourceJosep Carreras Leukaemia Research Institute·JournalCancer Research Communications·TypeExperimental study·DateFeb 5, 2024
Researchers at the John Theurer Cancer Center have co-authored a study on oral decitabine-cedazuridine therapy, which is now shown to be pharmacologically and pharmacodynamically equivalent to its intravenous counterpart. This innovation has significant potential for patient benefit and improved comfort in cancer treatment.
SourceHackensack Meridian Health·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJan 31, 2024
A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.
SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateJan 29, 2024
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers found decreased BMAd density and altered distribution profile in MGUS patients who developed MM, indicating early changes in bone marrow adipose tissue. These findings suggest the potential for timely interventions and personalized treatment strategies.
SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateJan 22, 2024
Researchers have identified a significant link between inherited genetic variants and the development of rare blood cancer, myeloproliferative neoplasms (MPNs). Inherited genetic variants can influence whether a spontaneous mutation increases the risk of developing MPN.
SourceWellcome Trust Sanger Institute·JournalNature Genetics·DateJan 17, 2024
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateJan 16, 2024
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
SourceTechnical University of Munich (TUM)·JournalNature Cancer·TypeObservational study·DateJan 8, 2024
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateDec 28, 2023
A study published in Blood Advances found liso-cel to be a cost-effective treatment for r/r DLBCL, with a lower societal ICER of $68,212 per QALY. The treatment offered improved quality-adjusted life years and reduced lost productivity costs.
SourceAmerican Society of Hematology·JournalBlood Advances·DateDec 28, 2023
A new study found that removing the RUNX1 transcription factor and its target gene can lead to a network collapse, causing cancer cell death in a type of aggressive leukemia. This breakthrough identifies specific protein targets for potential treatments.
SourceUniversity of Birmingham·JournalCell Reports·TypeObservational study·DateDec 20, 2023
A microbial sensor, Nod1, plays a crucial role in the development of blood stem cells. The discovery could lead to the creation of patient-derived blood stem cells, eliminating the need for bone marrow transplants and improving lives of leukemia, lymphoma, and anemia patients. Researchers are continuing to study the complex interaction...
SourceIowa State University·JournalNature Communications·TypeExperimental study·DateDec 19, 2023
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
Researchers investigated mechanisms of NK cell-mediated killing in various types of blood cancers, uncovering genes involved in sensitivity and resistance to NK cell therapies. The study aims to develop new personalized immunotherapies for improved cancer treatment outcomes.
SourceUniversity of Helsinki·JournalImmunity·DateDec 13, 2023
A phase III trial has found that personalised treatment for chronic lymphocytic leukaemia (CLL) can improve survival and remission rates. The trial showed that individualising therapy based on regular blood tests significantly improved progression-free and overall survival in patients with previously untreated CLL.
SourceUniversity of Leeds·JournalNew England Journal of Medicine·DateDec 10, 2023
A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...
SourceUniversity of Pennsylvania School of Medicine·JournalMolecular Cancer·DateDec 9, 2023
Apple AirPods Pro (2nd Generation, USB-C)
Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
Studies at single-cell resolution reveal significant tumor cell heterogeneity and an immune-evasive environment that contributes to treatment resistance in T follicular helper cell lymphomas. A novel marker, PLS3, is also identified as a key player in this process.
SourceUniversity of Tsukuba·JournalLeukemia·DateDec 5, 2023
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
A recent study by Goethe University Frankfurt has identified a mechanism that could be a suitable starting point for developing novel drugs against leukemia cells. The researchers discovered that the mutated NPM1 gene variant drives pro-autophagic activity, enabling cancer cells to recycle their structures and meet their needs.
SourceGoethe University Frankfurt·JournalCell Reports·TypeExperimental study·DateDec 4, 2023
Researchers at Goethe University Frankfurt have identified a specific gene locus, MYNRL15, that is critical to the survival and replication of leukemia cells. Inhibiting this gene has been shown to deactivate genes necessary for AML cell survival, offering a new possibility for fighting leukemia.
SourceGoethe University Frankfurt·JournaliScience·TypeExperimental study·DateNov 22, 2023
Researchers discovered a 'genomic tug of war' between decitabine and H2A.Z in animal studies, which could influence how well patients respond to decitabine. High levels of H2Z may help cancer cells overcome this effect, allowing them to grow.
SourceUniversity of Rochester Medical Center·JournalDevelopment·TypeExperimental study·DateNov 16, 2023
Researchers discovered a link between gene therapy and the accumulation of stem cells with genetic mutations, which can lead to accelerated growth and increased blood cancer risk. The study suggests that younger patients may be safer candidates for gene therapy due to fewer genetic mutations.
SourceUniversity of York·JournalNature Medicine·TypeExperimental study·DateNov 16, 2023
A novel droplet digital PCR assay detects KMT2A fusion markers in AML patients, enabling sensitive MRD detection and guiding treatment decisions. This breakthrough may improve patient outcomes by assessing response to therapy and long-term surveillance.
SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateNov 13, 2023
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
A multinational study of almost one million individuals found a strong association between exposure to radiation from CT scans in young people and an increased risk of blood cancers. The study confirms that the benefits of computed tomography outweigh the risks, but emphasizes the need for strict radiological protection measures, parti...
SourceBarcelona Institute for Global Health (ISGlobal)·JournalNature Medicine·TypeData/statistical analysis·DateNov 9, 2023
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
SourceUniversity of Gothenburg·JournalObesity·TypeObservational study·DateNov 6, 2023
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
SourceUniversity of Pittsburgh·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateOct 19, 2023
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.
SourceUniversity of Texas at Austin·JournalCancer Cell·TypeExperimental study·DateOct 9, 2023
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
A study published in Blood Advances found that diabetes is associated with poorer survival rates in white patients with multiple myeloma, but not Black patients. Researchers believe higher insulin levels may accelerate cancer growth.
SourceAmerican Society of Hematology·JournalBlood Advances·DateSep 29, 2023